Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 7, 2008, Pages 465-471

  Wang, Furong ^a,c   Gao, Ling ^a   Gong, Bendi ^b   Hu, Jianting ^a   Li, Mei ^a   Guan, Qingbo ^a   Zhao, Jiajun ^a  

^a SHANDONG UNIVERSITY   (China)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

cAMP; Cilostazol; Diabetes; Peroxisome proliferator activated receptors

Indexed keywords

CILOSTAZOL; CYCLIC AMP; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; KIDNEY CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES;

ANIMALS; AORTA, THORACIC; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; KIDNEY CORTEX; MALE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLES;

EID: 46749157847     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-043     Document Type: Article

References (25)

1. Braissant, O., Foufelle, F., Scotto, C., Dauça, M., and Wahli, W. 1996. Differential expression of peroxisome proliferatoractivated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology, 137: 354-366. doi:10. 1210/en.137.1.354. PMID:8536636.
2. Busik, J.V., Chen, W., Jump, D.B., Grant, M.B., and Esselman, W.J. 2005. Anti-inflammatory effect of PPARα in human retinal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 46: 4708.
3. Calkin, A.C., Giunti, S., Jandeleit-Dahm, K.A., Allen, T.J., Cooper, M.E., and Thomas, M.C. 2006. PPAR-{alpha} and {gamma} agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol. Dial. Transplant. 21: 2399-2405. doi:10.1093/ndt/gfl212. PMID:16720596.
4. Cone, J., Wang, S., Tandon, N., Fong, M., Sun, B., Sakurai, K., et al. 1999. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol. 34: 497-504. doi:10.1097/00005344-199910000-00004. PMID:10511123.
5. Ding, X., Saxena, N.K., Lin, S., Gupta, N.A., Gupta, N., and Anania, F.A. 2006. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 43: 173-181. doi:10.1002/hep.21006. PMID:16374859.
6. Gao, L., Wang, F.R., Wang, B., Gong, B., Zhang, J., Zhang, X., et al. 2006. Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappaB-dependent down-regulation of vascular cell adhesion molecule-1 expression. J. Pharmacol. Exp. Ther. 318: 53-58. doi:10.1124/jpet.106. 101444. PMID: 16595735.
7. Gizard, F., Amant, C., Barbier, O., Bellosta, S., Robillard, R., Percevault, F., et al. 2005. PPARα? inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16 INK4a. J. Clin. Invest. 115: 3228-3238. doi:10.1172/JCI22756. PMID:16239970.
8. Gu, Z., Jiang, Q., and Yan, Z. 2007. RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol. Pharmacol. 71: 1030-1039. doi:10.1124/mol.106.032490. PMID:17220354.
9. Kanie, N., Matsumoto, T., Kobayashi, T., and Kamata, K. 2003. Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endotheliumdependent relaxation in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 140: 23-32. doi:10.1038/sj.bjp.0705414. PMID: 12967931.
10. Kim, S.K., Zhao, Z.S., Lee, Y.J., Lee, K.E., Kang, S.M., Choi, D., et al. 2003. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab. Res. Rev. 19: 487-493. doi:10.1002/dmrr.410. PMID:14648808.
11. Kliewer, S.A., Forman, B.M., Blumberg, B., Ong, E.S., Borgmeyer, U., Mangelsdorf, D.J., et al. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 91: 7355-7359. doi:10.1073/pnas.91.15.7355. PMID:8041794.
12. Li, X., Kimura, H., Hirota, K., Sugimoto, H., Kimura, N., Takahashi, N., et al. 2007. Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-g in human proximal renal tubular cells. Nephrol. Dial. Transplant. 22: 1041-1051. doi:10.1093/ndt/gfl766. PMID:17255125.
13. Lim, S., Jin, C.J., Kim, M., Chung, S.S., Park, H.S., Lee, I.K., et al. 2006. PPARg gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler. Thromb. Vasc. Biol. 26: 808-813. doi:10.1161/01.ATV. 0000204634.26163.a7. PMID:16424348.
14. Lindgren, E.M., Nielsen, R., Petrovic, N., Jacobsson, A., Mandrup, S., Cannon, B., et al. 2004. Noradrenaline represses PPAR-gamma2 gene expression in brown adipocytes: intracellular signalling and effects on PPARgamma2 and PPARgamma1 protein levels. Biochem. J. 382: 597-606. PMID:15193150.
15. Liu, Y., Shakur, Y., Yoshitake, M., and Ji, J.K. 2001. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc. Drug Rev. 19: 369-386. PMID:11830753.
16. Mitsuhashi, N., Tanaka, Y., Kubo, S., Ogawa, S., Hayashi, C., Uchino, H., et al. 2004. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Endocr. J. 51: 545-550. doi:10.1507/endocrj.51.545. PMID: 15644572.
17. Ohga, S., Shikata, K., Yozai, K., Okada, S., Ogawa, D., Usui, H., et al. 2007. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory. effects mediated by inhibition of NF-κB activation. Am. J. Physiol. Renal Physiol. 292: F1141-F1150. PMID:17190910.
18. Panchapakesan, U., Sumual, S., Pollock, C.A., and Chen, X. 2005. PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am. J. Physiol. Renal Physiol. 289: F1153-F1158. doi:10.1152/ajprenal.00097.2005. PMID:15886275.
19. Park, C.W., Kim, H.W., Ko, S.H., Chung, H.W., Lim, S.W., Yang, C.W., et al. 2006. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor α. Diabetes, 55: 885-893. doi:10.2337/diabetes.55.04.06.db05-1329. PMID:16567507.
20. Pozzi, A., Ibanez, M.R., Gatica, A.E., Yang, S., Wei, S., Mei, S., et al. 2007. Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis. J. Biol. Chem. 282: 17685-17695. doi:10.1074/jbc.M701429200. PMID:17405874.
21. Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., et al. 1998. Expression of the peroxisome proliferator-activated receptor gamma in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 95: 7614-7619. doi:10.1073/pnas.95.13.7614. PMID:9636198.
22. Sartippour, M.R., and Renier, G. 2000. Differential regulation of macrophage peroxisome proliferator -activated receptor expression by glucose: role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. Arterioscler. Thromb. Vasc. Biol. 20: 104-110. PMID:10634806.
23. Srinivasan, S., Hatley, M.E., Reilly, K.B., Danziger, E.C., and Hedrick, C.C. 2004. Modulation of PPARα expression and inflammatory interleukin-6 production by chronic glucose increases monocyte/endothelial adhesion. Arterioscler. Thromb. Vasc. Biol. 24: 851-857. doi:10.1161/01.ATV. zhq0504.2260. PMID:15001458.
24. Tohma, T., Shimabukuro, M., Oshiro, Y., Yamakawa, M., Shimajiri, Y., Takasu, N., et al. 2004. Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. Metabolism, 53: 1405-1410. doi:10.1016/j.metabol.2004.06.005. PMID:15536593.
25. Verreth, W., De Keyzer, D., Pelat, M., Verhamme, P., Ganame, J., Bielicki, J.K., et al. 2004. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator- activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation, 110: 3259-3269. doi:10.1161/01.CIR.0000147614.85888.7A. PMID:15533870.